With brain infusions, a growth factor called glial-derived neurotrophic factor (GDNF) is placed in the part of the brain where dopamine is lacking in the hope of encouraging the damaged cells to rejuvenate and produce more dopamine.
Although initial results were promising, the outcome of later studies was very mixed. Because of this and safety issues, Amgen, the pharmaceutical company involved has stopped making GDNF, despite the fact that some researchers disagree with this decision.
A neurotransmitter produced in the substantia nigra, which forms part of the basal gangia in the brain. It sends messages from the brain to other parts of the body and has a major role in the control of movement. There is a shortage of dopamine in the brains of people with Parkinson's disease.
A nerve growth factor that helps develop and control several types of nerve cells, including those that produce dopamine. Used in gene therapy and brain infusion surgery to treat Parkinson’s disease.
